Cg Oncology (CGON) | Stock Overview & Key Data
Cg Oncology Performance Comparison
Stock Range
Today's Range
Low: $26.92
High: $29.00
on September 3, 2025
52 Week Range
Low: $14.80
High: $40.47
on April 9, 2025
on November 11, 2024
All-Time High: $50.23 on February 12, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.9B
EPS
-1.78
P/E Ratio (TTM)
-19.48
Forward P/E
-15.43
P/B Ratio
3.12
PEG Ratio
-0.21
Div. Yield
N/A
ROE
-12.00%
Beta
N/A
Debt to Equity
0.15
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-28,546.10%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-11.66%
Return on Equity (TTM)
-12.00%
EBITDA
$-157.1M
Net Income (TTM)
$-128.1M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.01
Quarterly Revenue Growth (YoY)
-100.00%
Quarterly Earnings Growth (YoY)
-100.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Cg Oncology CGON | 1.91B Small-cap | 8.27% | 9.89% | 7.02% | 14.22% | -1.04% | -24.65% | -18.16% | -18.16% |
| Vertex VRTX | 102.81B Large-cap | 1.94% | -16.02% | -11.17% | -17.94% | -2.25% | -15.25% | 35.78% | 53.75% |
| Regeneron REGN | 61.25B Large-cap | -3.95% | -1.35% | 15.57% | -17.68% | -21.17% | -50.17% | -22.16% | 3.50% |
| Centessa CNTA | 1.98B Small-cap | -4.44% | -1.06% | 19.09% | 5.78% | -9.09% | 11.26% | 293.81% | -26.85% |
| Kymera Therapeutics KYMR | 1.96B Small-cap | 2.46% | -0.82% | -0.64% | 43.52% | 5.89% | -4.63% | 47.53% | 38.83% |
| Agios AGIO | 1.90B Small-cap | 3.41% | 12.31% | 21.70% | 22.61% | 27.54% | -6.17% | 18.95% | 9.85% |
Ownership & Short Interest
Insider Ownership
1.17%
Institutional Ownership
112.62%
Shares Short
10M
Short Ratio
11.25
Short % of Shares Outstanding
14.34%
Average 10-Day Volume
435K
Average 90-Day Volume
710K
Warning: Undefined variable $nickname in /usr/local/lsws/wordpress/wp-content/themes/egnitech-devyara/templates/stock-overview.php on line 328
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is CGON's 52-week high and low?
- In the last 52 weeks, Cg Oncology reached a high of $40.47 (on November 11, 2024) and a low of $14.80 (on April 9, 2025).
- What is the market cap and P/E ratio for CGON?
- Curious about Cg Oncology's size and valuation? Its market capitalization stands at 1.91B. When it comes to valuation, the P/E ratio (trailing twelve months) is -19.48, and the forward P/E (looking ahead) is -15.43.
- Does CGON pay dividends? If so, what's the yield?
- As for dividends, Cg Oncology isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Cg Oncology's main competitors or similar companies to consider before investing?
When looking at Cg Oncology, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX102.81B Healthcare Biotechnology -15.25% 35.78% Regeneron
REGN61.25B Healthcare Biotechnology -50.17% -22.16% Centessa
CNTA1.98B Healthcare Biotechnology 11.26% 293.81% Kymera Therapeutics
KYMR1.96B Healthcare Biotechnology -4.63% 47.53% Agios
AGIO1.90B Healthcare Biotechnology -6.17% 18.95% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Cg Oncology, Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Cg Oncology's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -12.00%, the Debt to Equity ratio from the most recent quarter is 0.15, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for CGON?
- Looking at Cg Oncology's growth, its revenue over the trailing twelve months (TTM) was $551K. Compared to the same quarter last year (YoY), quarterly revenue grew by -100.00%, and quarterly earnings saw a YoY growth of -100.00%.
- How much of CGON stock is held by insiders and institutions?
- Wondering who owns Cg Oncology stock? Company insiders (like executives and directors) hold about 1.17% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 112.62%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.